Biotech Stocks Drop Sharply; Rapport Therapeutics, Climb Bio and Cullinan Therapeutics Among the Worst Performers
Biotech stocks fell significantly on Wednesday, with several companies in the Medical-Development Biotech industry group experiencing sharp declines. Rapport Therapeutics (RAPP), Climb Bio (CLYM) and Cullinan Therapeutics (CGEM) were among those hit hardest by the sell-off. The broader biotech sector includes over 500 publicly traded firms that have not yet launched commercial products, and this group dropped collectively by 4%. The decline placed it at number 30 out of 145 industry groups in terms of performance. Market participants are likely reacting to a combination of sector-specific concerns or broader market sentiment affecting high-risk biotech stocks.
Topics: Biotech stocks Market decline